Alaunos Therapeutics, Inc. Capital Expenditures Incurred but Not yet Paid
Alaunos Therapeutics, Inc. (TCRT) reported Capital Expenditures Incurred but Not yet Paid of $0 for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalExpendituresIncurredButNotYetPaid · last filed 2024-05-15
- Alaunos Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Alaunos Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-12-31 was -$1.00K.
- Alaunos Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-09-30 was $1.00K, a 99.70% decline year-over-year.
- Alaunos Therapeutics, Inc. capital expenditures incurred but not yet paid for the quarter ending 2023-06-30 was -$101.00K.
- Alaunos Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- Alaunos Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2022 was $91.00K, a 32.09% decline from fiscal 2021.
- Alaunos Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2021 was $134.00K, a 71.55% decline from fiscal 2020.
- Alaunos Therapeutics, Inc. capital expenditures incurred but not yet paid for fiscal 2020 was $471.00K.
| Period end | Capital Expenditures Incurred but Not yet Paid 3 month | Capital Expenditures Incurred but Not yet Paid 6 month | Capital Expenditures Incurred but Not yet Paid 9 month | Capital Expenditures Incurred but Not yet Paid 9 month as first filed | Capital Expenditures Incurred but Not yet Paid 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | -$1.00K derived: sum of 2 quarters · filed 2024-05-15 | $0.00 derived: sum of 3 quarters · filed 2024-05-15 | -$101.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2023-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $0.00 derived: sum of 2 quarters · filed 2024-04-01 | -$101.00K derived: sum of 3 quarters · filed 2024-04-01 | $0.00 10-K · filed 2024-04-01 | |
| 2023-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$100.00K derived: sum of 2 quarters · filed 2023-11-14 | $1.00K 10-Q · filed 2023-11-14 | -$256.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2023-06-30 | -$101.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $0.00 10-Q · filed 2023-08-14 | -$257.00K derived: sum of 3 quarters · filed 2024-05-15 | $74.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2023-03-31 | $101.00K 10-Q · filed 2024-05-15 | -$156.00K derived: sum of 2 quarters · filed 2024-05-15 | $175.00K derived: sum of 3 quarters · filed 2024-05-15 | $163.00K derived: sum of 4 quarters · filed 2024-05-15 | |
| 2022-12-31 | -$257.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $74.00K derived: sum of 2 quarters · filed 2024-04-01 | $62.00K derived: sum of 3 quarters · filed 2024-04-01 | $91.00K 10-K · filed 2024-04-01 | |
| 2022-09-30 | $331.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $319.00K derived: sum of 2 quarters · filed 2023-11-14 | $348.00K 10-Q · filed 2023-11-14 | $74.00K 10-Q · filed 2022-11-14 | $134.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $17.00K 10-Q · filed 2023-08-14 | -$197.00K derived: sum of 3 quarters · filed 2023-08-14 | -$107.00K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $29.00K 10-Q · filed 2023-05-10 | -$185.00K derived: sum of 2 quarters · filed 2023-05-10 | -$95.00K derived: sum of 3 quarters · filed 2023-05-10 | -$519.00K derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | -$214.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | -$124.00K derived: sum of 2 quarters · filed 2023-03-07 | -$548.00K derived: sum of 3 quarters · filed 2023-03-07 | $134.00K 10-K · filed 2023-03-07 | |
| 2021-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$334.00K derived: sum of 2 quarters · filed 2022-11-14 | $348.00K 10-Q · filed 2022-11-14 | -$344.00K derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$424.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $258.00K 10-Q · filed 2022-08-15 | -$434.00K derived: sum of 3 quarters · filed 2022-08-15 | -$297.00K derived: sum of 4 quarters · filed 2022-08-15 | |
| 2021-03-31 | $682.00K 10-Q · filed 2022-05-16 | -$10.00K derived: sum of 2 quarters · filed 2022-05-16 | $127.00K derived: sum of 3 quarters · filed 2022-05-16 | -$1.15M derived: sum of 4 quarters · filed 2022-05-16 | |
| 2020-12-31 | -$692.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | -$555.00K derived: sum of 2 quarters · filed 2022-03-30 | -$1.83M derived: sum of 3 quarters · filed 2022-03-30 | $471.00K 10-K · filed 2022-03-30 | |
| 2020-09-30 | $137.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$1.14M derived: sum of 2 quarters · filed 2021-11-08 | $1.16M 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | -$1.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $1.03M 10-Q · filed 2021-08-13 | |||
| 2020-03-31 | $2.30M 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |